INMB

INmune Bio Inc

Oct 13 • 04:00PM ET

1.83

-0.03 -1.61 %

Healthcare • Biotechnology • USA • NASD

Peers: ABUS SLNO LPTX ONCY TNXP PDSB IMUX BGMS PRQR LITS

| Held by: VTI IWM IWO VXF VTWO IWC VTWG RSSL MSSM VTHR

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	28.90%	Shs Outstand	26.59M	Perf Week	-11.17%
Market Cap	48.65M	Forward P/E	-	EPS next Y	-1.44	Insider Trans	0.00%	Shs Float	18.90M	Perf Month	-8.96%
Enterprise Value	15.73M	PEG	-	EPS next Q	-0.32	Inst Own	21.23%	Short Float	17.35%	Perf Quarter	-11.59%
Income	-55.51M	P/S	973.05	EPS this Y	20.85%	Inst Trans	-5.14%	Short Ratio	2.27	Perf Half Y	-75.20%
Sales	0.05M	P/B	1.69	EPS next Y	13.77%	ROA	-123.16%	Short Interest	3.28M	Perf YTD	-60.81%
Book/sh	1.09	P/C	1.46	EPS next 5Y	14.56%	ROE	-168.34%	52W High	11.64 -84.28%	Perf Year	-64.40%
Cash/sh	1.26	P/FCF	-	EPS past 3/5Y	-3.91% -23.07%	ROIC	-190.76%	52W Low	1.71 7.02%	Perf 3Y	-72.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-57.39% -	Gross Margin	-	Volatility	5.44% 5.42%	Perf 5Y	-82.78%
Dividend TTM	-	EV/Sales	314.65	EPS Y/Y TTM	-21.12%	Oper. Margin	-79430.00%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.20	Sales Y/Y TTM	-41.18%	Profit Margin	-111016.00%	RSI (14)	37.02	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	4.20	EPS Q/Q	-107.96%	SMA20	-8.41%	Beta	0.99	Target Price	6.33
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-15.04%	Rel Volume	0.33	Prev Close	1.86
Employees	22	LT Debt/Eq	0.01	Earnings	Aug 07 AMC	SMA200	-67.30%	Avg Volume	1.45M	Price	1.83
IPO	Feb 04, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-173.44% -	Trades		Volume	475,429	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform	$0.60
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$23
Oct-21-24	Initiated	Alliance Global Partners	Buy	$20
Sep-27-24	Initiated	Raymond James	Outperform	$18
Aug-22-24	Initiated	Scotiabank	Sector Outperform	$22
Jun-01-23	Initiated	Robert W. Baird	Outperform	$16
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral	$14 → $7
Jul-07-21	Reiterated	Maxim Group	Buy	$32 → $42
Apr-21-21	Initiated	B. Riley Securities	Buy	$29
Jan-22-21	Reiterated	Maxim Group	Buy	$16 → $32
Sep-01-20	Initiated	BTIG Research	Buy	$23
Jul-15-20	Reiterated	H.C. Wainwright	Buy	$7 → $20

Show Previous Ratings

Sep-29-25 08:00AM	INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal (GlobeNewswire)
Sep-15-25 08:00AM	INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom at CGT Catapult (GlobeNewswire)
Sep-08-25 04:50PM	INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.18%
Aug-07-25 04:05PM	INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes (GlobeNewswire) -8.24%
Aug-04-25 08:00AM	INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment (GlobeNewswire) +11.52%
07:00AM	Loading…
Jul-31-25 07:00AM	INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th (GlobeNewswire)
Jul-29-25 07:00AM	INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro Presented at the Alzheimer's Association International Conference (GlobeNewswire) +8.59%
Jul-24-25 07:00AM	INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference (GlobeNewswire)
Jul-01-25 01:37PM	INmune slides again as Scotiabank, RJ cut ratings after Alzheimers drug miss (Investing.com) -9.52%
Jun-30-25 04:05PM	INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -56.66%
08:16AM	INmune Bio stock plummets after mixed Phase 2 Alzheimers trial results (Investing.com)
07:30AM	INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease (GlobeNewswire)
Jun-27-25 12:16PM	INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.13%
Jun-26-25 04:00PM	INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th (GlobeNewswire) -14.79%
Jun-10-25 04:00PM	XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense (GlobeNewswire)
08:00AM	Loading…
May-14-25 08:00AM	INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) -7.82%
May-08-25 04:10PM	INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
May-07-25 11:23AM	INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-05-25 07:00AM	INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 07:00AM	INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology (GlobeNewswire)
Apr-15-25 07:42AM	INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms (Pharmaceutical Business Review)
Apr-14-25 08:00AM	INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness (GlobeNewswire)
Apr-01-25 07:00AM	INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study (GlobeNewswire)
Mar-28-25 03:04AM	INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Mar-27-25 08:15PM	INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update (GlobeNewswire)
Mar-24-25 08:00AM	INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-21-25 01:15PM	Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + (SeekingAlpha)
Mar-02-25 09:28AM	Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 (Insider Monkey)
09:51AM	Loading…
Feb-12-25 09:51AM	INmune Bio price target raised to $23 from $22 at Scotiabank (TipRanks) +10.67%
07:00AM	INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer (GlobeNewswire)
Feb-10-25 07:00AM	INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Feb-03-25 08:11PM	Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 (Insider Monkey)
Jan-28-25 08:00AM	INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Dec-10-24 08:00AM	INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt (GlobeNewswire)
Dec-04-24 02:51PM	OmniScience and INmune Bio Partner for Alzheimers Trial (Exec Edge)
09:00AM	OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower (Business Wire)
Nov-13-24 09:00AM	INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Nov-01-24 11:01AM	INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Oct-31-24 04:05PM	INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Oct-30-24 09:22AM	INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.56%
Oct-28-24 08:00AM	INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB (GlobeNewswire) +13.75%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares (GuruFocus.com)
Oct-24-24 03:03PM	INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination (GlobeNewswire)
09:30AM	INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 (GlobeNewswire)
Oct-11-24 08:30AM	INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 03:51PM	INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 08:00AM	INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Sep-26-24 08:00AM	INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort (GlobeNewswire)
Sep-17-24 08:30AM	INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints (GlobeNewswire)
Sep-13-24 08:30AM	INmune Bio Announces $13.0 Million Registered Direct Offering (GlobeNewswire) -14.55%
Sep-03-24 09:00AM	INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference (GlobeNewswire) -7.10%
Aug-01-24 04:05PM	INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) -7.92%
Jul-29-24 09:00AM	INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro on Proteins that Regulation Synapses in Alzheimer's Patients (GlobeNewswire)
Jul-25-24 08:00AM	INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 (GlobeNewswire)
Jul-23-24 08:45AM	INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Jun-28-24 12:13PM	INmune Bios unique Alzheimers trial endpoint receives validation (Clinical Trials Arena)
Jun-27-24 08:00AM	INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial (GlobeNewswire) +19.20%
May-30-24 08:00AM	INmune Bio Inc. to Join Russell 3000 Index (GlobeNewswire)
May-13-24 11:54AM	INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update (GlobeNewswire) -6.96%
May-07-24 08:00AM	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 (GlobeNewswire)
Apr-30-24 08:00AM	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years (GlobeNewswire)
Apr-29-24 08:00AM	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-25-24 09:00AM	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Apr-23-24 08:00AM	INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay (GlobeNewswire)
Apr-22-24 08:00AM	INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering (GlobeNewswire) +26.94%
Apr-08-24 08:00AM	INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 (GlobeNewswire)
Apr-01-24 10:20AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31PM	INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements (GuruFocus.com)
Mar-28-24 08:53PM	INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update (GlobeNewswire)
Mar-26-24 04:01PM	INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 (GlobeNewswire)
Mar-13-24 08:00AM	INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy (GlobeNewswire)
Mar-05-24 08:00AM	INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro (GlobeNewswire) -5.37%
Feb-12-24 09:00AM	INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 09:00AM	INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024 (GlobeNewswire)
Jan-30-24 08:00AM	INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program (GlobeNewswire) -7.52%
Jan-16-24 08:30AM	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology (GlobeNewswire) -6.72%
Jan-02-24 08:00AM	INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Dec-18-23 04:01PM	INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA (GlobeNewswire) +7.97% -9.29%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
08:00AM	INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 08:00AM	INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease (GlobeNewswire)
Nov-17-23 08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-15-23 09:00AM	INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe (GlobeNewswire)
Nov-02-23 10:11AM	INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:54AM	Q3 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 06:44PM	INmune Bio Inc (INMB) Reports Q3 2023 Financial Results (GuruFocus.com)
04:10PM	INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Oct-31-23 08:00AM	INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune Therapeutic Composition given Favorable Patentability Opinion by International Search Authority (GlobeNewswire) +7.84%
Oct-30-23 09:07AM	INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRP (GlobeNewswire)
Oct-25-23 09:00AM	Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting (PR Newswire)
Oct-17-23 08:00AM	INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +10.32%
Oct-16-23 09:00AM	INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 (GlobeNewswire)
Sep-07-23 09:00AM	INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-05-23 08:00AM	INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimers Disease (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey) -5.82%

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer's disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INMB

INmune Bio Inc

Upgrade your FINVIZ experience